Fischer Medical Ventures Limited (FISCHER) marked a significant milestone with the launch of the CLARION 64/128-Slice AI-Driven CT System, a breakthrough in medical imaging technology. This launch, held at the India Health Expo 2026, was a testament to FISCHER’s commitment to advancing intelligent, efficient, and sustainable healthcare delivery.

Advanced Technology for Enhanced Diagnostics

The CLARION CT platform integrates high-performance imaging hardware with AI-driven workflow capabilities, supporting greater diagnostic precision, operational efficiency, and patient throughput. The system’s advanced Liquid Metal Bearing (LMB) X-ray tube with 360° liquid metal cooling ensures superior heat dissipation, stable focal spot positioning, and continuous high-speed operation.

Innovative Features for Clinical Applications

The CLARION platform’s intelligent workflow capabilities include three-click scanning, AI-assisted automatic patient positioning, and remote-control functionality. These features simplify CT operations and improve workflow efficiency. The system’s scalable configurations extend up to 128 slices, addressing routine diagnostic imaging to advanced cardiac, vascular, neurological, thoracic, abdominal, orthopaedic, and interventional applications.

Future-Ready Medical Imaging

The launch signifies another step towards enabling healthcare institutions to deliver faster, more precise, efficient, and technology-enabled diagnostic and interventional care across India. With the introduction of the CLARION 64/128-Slice AI-Driven CT System, FISCHER continues to build a comprehensive medical imaging ecosystem that integrates advanced engineering, artificial intelligence, and intelligent clinical workflows.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fischer Medical Ventures Limited

Fischer Medical Ventures Limited belongs to the Healthcare › Medical Devices sector. Here’s a quick read on where the business and the stock stand today.

Fischer trades in the lower quarter of its 52-week range. Thin margins at 8.2% leave limited room for error — any demand softness or cost spike hits the bottom line hard. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock sits at 4% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 1097.9% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Fischer Medical Ventures Limited.

Fischer Medical Ventures Limited (NSE: FISCHER) has made a significant announcement today, revealing that its subsidiary, Time Medical Philippines (TM-P), has been awarded a province-wide digital healthcare project for Catanduanes Province. This project marks an important milestone in the digitalization of Universal Health Care (UHC) in the Philippines.

Integrated Digital Healthcare Solution

The project involves deploying an integrated healthcare solution combining Health Kiosks with the PhilHealth-accredited FlynnCare Clinic Management System (CMS). This initiative aims to connect community-level healthcare delivery with structured digital clinical workflows and patient information, thereby making quality healthcare more accessible and digitally enabled across communities.

Supporting the Philippine Government’s UHC Program

Fischer Medical Ventures and Time Medical Philippines are fully committed to supporting the Philippine Government’s Universal Health Care priority program under President Ferdinand “Bongbong” Romualdez Marcos Jr. The Catanduanes rollout represents an important first step in translating this vision into a scalable province-wide digital healthcare model.

As healthcare systems continue to modernize, this integrated approach provides opportunities for scalable deployments, long-term technology support, and sustainable recurring revenue models across multiple markets.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fischer Medical Ventures Limited

Fischer Medical Ventures Limited belongs to the Healthcare › Medical Devices sector. Here’s a quick read on where the business and the stock stand today.

Fischer rises 10.8% over three months, with buying pressure holding steady. 2 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock sits at 8% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. The stock rises 10.8% in three months on 1097.9% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Fischer Medical Ventures Limited.

Fischer Medical Ventures Limited (NSE: FISCHER) has announced a strategic partnership with Parul Sevashram Hospital, Vadodara, to install its revolutionary DRIS–iMRI Medharanya Suite, an AI-enabled next-generation portable intraoperative MRI system. This collaboration aims to transform neurosurgical procedures by providing surgeons with real-time visualization, enhancing precision and safety.

Advanced Neurosurgical Imaging

The DRIS–iMRI Medharanya Suite integrates augmented reality, artificial intelligence, machine learning, and exoscope technologies into a single, intelligent surgical ecosystem. This advanced imaging modality is designed to unify diagnostic and surgical workflows, enabling faster decision-making and unparalleled visualization of complex neurological anatomy.

Strategic Collaboration

This partnership aligns with Fischer Medical Ventures Limited’s focus on expanding access to advanced imaging technologies. The DRIS–iMRI Medharanya Suite is expected to strengthen Parul Sevashram Hospital’s academic and clinical ecosystem, offering medical students and faculty hands-on exposure to next-generation neurosurgical imaging technology.

As a result, this initiative will enhance neurosurgical precision, improve clinical outcomes, and strengthen advanced neurocare capabilities at the hospital. This landmark deployment marks a significant step in advancing neurosurgical care in India.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fischer Medical Ventures Limited

Fischer Medical Ventures Limited belongs to the Healthcare › Medical Devices sector. Here’s a quick read on where the business and the stock stand today.

Fischer posts a 2.8% three-month gain, but softens in the last few weeks. 2 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock gives back 6.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 1097.9% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Fischer Medical Ventures Limited.